3D Systems partners to sell dental printers; U.K. calls for suspension of vaginal mesh implants;

@FierceMedDev: Startup Akili partners with nonprofit Autism Speaks to test video game. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI: More lawsuits planned as infected endoscope safety scare grows. More | Follow @VarunSaxena2

> Henry Schein ($HSIC) will sell 3D Systems' ($DDD) dental 3-D printers to its customers in the United States, Canada, France, Germany, Australia and Thailand. The printers can be used to create wax and working model versions of crowns, bridges and partial denture frameworks. More

> Musculoskeletal implant maker Globus Medical ($GMED) is acquiring medical device manufacturer Branch Medical Group for $53 million. The expectation is to expand the number of medical devices made by BMG. Release

> The FDA's General and Plastic Surgery Devices Panel voted in favor of recommending the expansion of the indication for Merz's Radiesse Dermal Filler to include hand augmentation for volume correction. It's already approved for facial use. Story

> U.K. Health Secretary Shona Robison is calling for the suspension of vaginal mesh implants. The procedures continued despite a moratorium by former health secretary Alex Neil in June of last year Story

Biotech News

@FierceBiotech: From FierceDrugDelivery: UPDATED: @US_FDA agrees to review $ENDP's inside-the-cheek pain drug. More | Follow @FierceBiotech

@JohnCFierce: Interested in ADCs and VC cash? Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm. Article | Follow @JohnCFierce

@DamianFierce: The fake Immunovaccine release reads like a parody of bio stock pumping. Image | Follow @DamianFierce

> As PhII data looms, Chugai inks a $205M stem cell deal with Athersys. Article

> Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease. Report

> China biotech makes FDA 'breakthrough' for HIV drug. Item

Pharma News

@FiercePharma: Oculus leaps into animal health with 6 new skin and eye products. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bayer counts on consumer health, pharma growth to power 2015. Story | Follow @CarlyHFierce

> AstraZeneca director pushing to tie exec pay to big growth promises. Report

> Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what? Story

> GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge. More

Biotech IT News

> RainDance files for $60M IPO. Item

> Novo Nordisk set to rake in up to $335M from IT unit IPO. Report

> Eccrine bags seed funding for Air Force-developed sweat sensor. News

> Analyst casts doubt on Big Data potential of Covance-LabCorp merger. Story

> H3 hooks up with Foundation Medicine for data-driven oncology R&D. Article

CRO News

> Charles River embraces discovery in management shake-up. News

> Catalent beefs up its European network for clinical supplies. Story

> Enteris gets into contract manufacturing with new plant. Item

> INC Research soars in its first post-IPO quarter. Report

> Icon rides a revenue leap into another growth year. Article

Animal Health News

> Bayer to close animal health plant in St. Joseph, MO; sell off some product lines. More

> Aratana regains dog lymphoma drug from Lilly for 'great price,' say analysts. Story

> Purina faces lawsuit over dogs allegedly sickened by Beneful. Item

> Oculus leaps into animal health with 6 new skin and eye products. Article

> Parnell records strong sales growth, stays focused on arthritis approval. Report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.